

Supplementary Files for “Treatment Outcomes of Blastocysts Thaw-Cycles, Comparing the Presence and Absence of a Corpus Luteum: A Systematic Review and Meta-analysis.

## Table of Contents

<b>Supplementary File 1</b> – Supplementary Table 1: Search Strategy .....	2
<b>Supplementary File 2</b> - Supplementary Table 2: Quality of Randomised Controlled Trials using the Revised Cochrane Risk-of-Bias tool 2.....	7
<b>Supplementary File 3</b> - Supplementary Table 3: Quality of Observational Studies using the Newcastle-Ottawa Scale .....	10
<b>Supplementary File 4</b> - Supplementary Figure 1: Funnel Plot Analyses .....	11
<b>Supplementary File 5</b> - Supplementary Figure 2: Meta-analysis comparing rates of positive hCG, clinical pregnancy and live births in cycles with and without a corpus luteum – separated by study design .....	12
<b>Supplementary File 6</b> - Supplementary Figure 3: Meta-analysis comparing rates of pregnancy losses in cycles with and without a corpus luteum – separated by study design .....	13
<b>Supplementary File 7</b> - Supplementary Figure 4: Meta-analysis comparing clinical pregnancy rates in cycles with and without a corpus luteum – sensitivity analysis .....	14

## Supplementary File 1 – Supplementary Table 1: Search Strategy

PUBMED/MEDLINE

Set	Search	Results
1	Cryopreservation[All Fields]	47,444
2	frozen embryo transfer[All Fields]	3,740
3	Frozen embryo*[All Fields]	8,561
4	frozen-thawed cycle[All Fields]	1,209
5	frozen-thawed embryo transfer[All Fields]	1,457
6	frozen thawed embryos[All Fields]	3,703
7	"FET"[All Fields]	3,577
8	cryopreserved embryos[All Fields]	9,714
9	Cryopreserved-thawed embryos[All Fields]	131
10	vitrification[All Fields]	4,568
11	Vitrified[All Fields]	3,077
12	"vitrified-warmed embryos"[All Fields]	440
13	"frozen-thawed"[All Fields]	5,134
14	embryo vitrification[All Fields]	2,144
15	blastocyst transfer[All Fields]	28,636
16	((((((((((((((cryopreservation) OR (frozen embryo transfer)) OR (frozen embryo*)) OR (frozen-thawed cycle)) OR (frozen-thawed embryo transfer)) OR (frozen thawed embryos)) OR (FET)) OR (cryopreserved embryos)) OR (cryopreserved-thawed embryos)) OR (vitrification)) OR (vitrified)) OR (vitrified-warmed embryos)) OR (frozen-thawed)) OR (embryo vitrification)) OR (blastocyst transfer))[All Fields]	81,001
17	endometrial preparation[All Fields]	2,129
18	natural cycle[All Fields]	56,766
19	ovulation induction[All Fields]	16,378
20	modified natural cycle[All Fields]	2,401
21	hormone therapy[All Fields]	659,266
22	Estrogen OR oestrogen OR oestrogens OR estrogens OR oestradiol[All Fields]	286,275
23	progesterone[All Fields]	119,710
24	stimulated cycle[All Fields]	63,307
25	stimulation of endometrium embryo transfer[All Fields]	426
26	artificial cycle	13,886
27	((((((((((endometrial preparation) OR (natural cycle)) OR (ovulation induction)) OR (modified natural cycle)) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol)) OR (progesterone)) OR (stimulated cycle)) OR (stimulation of endometrium embryo transfer)) OR (artificial cycle))[All Fields]	1,012,876
28	((((((((((endometrial preparation) OR (natural cycle)) OR (ovulation induction)) OR (modified natural cycle)) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol)) OR (progesterone)) OR (stimulated cycle)) OR (stimulation of endometrium embryo transfer)) OR (artificial cycle)) AND (((((((((((cryopreservation) OR (frozen embryo transfer)) OR	11,974

	(frozen embryo*) OR (frozen-thawed cycle) OR (frozen-thawed embryo transfer) OR (frozen thawed embryos) OR (FET) OR (cryopreserved embryos) OR (cryopreserved-thawed embryos) OR (vitrification) OR (vitrified) OR (vitrified-warmed embryos) OR (frozen-thawed) OR (embryo vitrification) OR (blastocyst transfer))[All Fields]	
29	Pregnancy[All Fields]	987,880
30	live birth*[All Fields]	32,374
31	miscarriage[All Fields]	47,358
32	ongoing pregnancy[All Fields]	8,897
33	clinical pregnancy[All Fields]	190,084
34	chemical pregnancy[All Fields]	45,767
35	(((((pregnancy) OR (live birth*)) OR (miscarriage)) OR (ongoing pregnancy)) OR (clinical pregnancy)) OR (chemical pregnancy) [All Fields]	1,001,238
36	((((((((((endometrial preparation) OR (natural cycle) OR (ovulation induction)) OR (modified natural cycle) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol) OR (progesterone)) OR (stimulated cycle) OR (stimulation of endometrium embryo transfer) OR (artificial cycle)) AND (((((((((((cryopreservation) OR (frozen embryo transfer) OR (frozen embryo*) OR (frozen-thawed cycle) OR (frozen-thawed embryo transfer) OR (frozen thawed embryos) OR (FET) OR (cryopreserved embryos) OR (cryopreserved-thawed embryos) OR (vitrification) OR (vitrified) OR (vitrified-warmed embryos) OR (frozen-thawed) OR (embryo vitrification) OR (blastocyst transfer))) AND ((((((pregnancy) OR (live birth*)) OR (miscarriage)) OR (ongoing pregnancy)) OR (clinical pregnancy)) OR (chemical pregnancy)) [All Fields]	7,913
37	animal[All Fields]	6,843,446
48	((((((((((((((endometrial preparation) OR (natural cycle) OR (ovulation induction)) OR (modified natural cycle) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol) OR (progesterone)) OR (stimulated cycle) OR (stimulation of endometrium embryo transfer) OR (artificial cycle)) AND (((((((((((cryopreservation) OR (frozen embryo transfer) OR (frozen embryo*) OR (frozen-thawed cycle) OR (frozen-thawed embryo transfer) OR (frozen thawed embryos) OR (FET) OR (cryopreserved embryos) OR (cryopreserved-thawed embryos) OR (vitrification) OR (vitrified) OR (vitrified-warmed embryos) OR (frozen-thawed) OR (embryo vitrification) OR (blastocyst transfer))) AND ((((((pregnancy) OR (live birth*)) OR (miscarriage)) OR (ongoing pregnancy)) OR (clinical pregnancy)) OR (chemical pregnancy))) NOT (animal) [All Fields]	6,386
39	((((((((((((((endometrial preparation) OR (natural cycle) OR (ovulation induction)) OR (modified natural cycle) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol) OR (progesterone)) OR (stimulated cycle) OR (stimulation of endometrium embryo transfer) OR (artificial cycle)) AND (((((((((((cryopreservation) OR (frozen embryo transfer) OR (frozen embryo*) OR (frozen-thawed cycle) OR (frozen-thawed	6,375

	embryo transfer)) OR (frozen thawed embryos)) OR (FET)) OR (cryopreserved embryos)) OR (cryopreserved-thawed embryos))) OR (vitrified-warmed embryos)) OR (frozen-thawed)) OR (embryo vitrification)) OR (blastocyst transfer))) AND ((((((pregnancy) OR (live birth*)) OR (miscarriage)) OR (ongoing pregnancy)) OR (clinical pregnancy)) OR (chemical pregnancy))) NOT (animal) [All Fields]	
40	(((((((((((endometrial preparation) OR (natural cycle)) OR (ovulation induction)) OR (modified natural cycle)) OR (hormone therapy)) OR (Estrogen or oestrogen or oestrogens or estrogens or estradiol)) OR (progesterone)) OR (stimulated cycle)) OR (stimulation of endometrium embryo transfer)) OR (artificial cycle)) AND ((((((((((((((cryopreservation) OR (frozen embryo transfer)) OR (frozen embryo*)) OR (frozen-thawed cycle)) OR (frozen-thawed embryo transfer)) OR (frozen thawed embryos)) OR (FET)) OR (cryopreserved embryos)) OR (cryopreserved-thawed embryos)) OR (vitrification)) OR (vitrified)) OR (vitrified-warmed embryos)) OR (frozen-thawed)) OR (embryo vitrification)) OR (blastocyst transfer))) AND ((((((pregnancy) OR (live birth*)) OR (miscarriage)) OR (ongoing pregnancy)) OR (clinical pregnancy)) OR (chemical pregnancy))) NOT (animal) [All Fields] - from 2017 - 2020	1,089

## EMBASE

Set	Search	Results
1	cryopreservation.mp. or cryopreservation/	45195
2	(Cryopreserv\$ adj7 embryo\$).tw.	5646
3	(Cryopreserv\$ adj7 blastocyst\$).tw.	1080
4	freezing/ or vitrification/	43414
5	(vitri\$ adj5 embryo\$).tw.	2410
6	(vitri\$ adj5 blastocyst\$).tw.	1803
7	(frozen adj5 embryo\$).tw.	5929
8	(freez\$ adj5 embryo\$).tw.	2056
9	(freez\$ adj5 blastocyst\$).tw.	367
10	(frozen adj5 blastocyst\$).tw.	1032
11	FET.tw.	4837
12	freeze thawing/ or freezing/	45930
13	vitrification/	5997
14	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13	95117
15	exp ovulation induction/	16413
16	((ovar\$ adj5 stimula\$) or (ovulat\$ adj5 induc\$)).tw.	26000
17	(endometri\$ adj2 prepar\$).tw.	1032
18	hormon\$ regimen\$.tw.	373
19	Clomiphene.tw. or Clomiphene/	11562
20	clomid.tw.	1284
21	(Tamoxifen or Letrozole).tw.	37754
22	aromatase inhibitor\$.tw.	11798
23	exp human menopausal gonadotropin/	10498
24	(Menotropin\$ or menopausal gonadotrop\$ or HMG).tw.	20554
25	exp follitropin/	64748

26	(Follicle Stimulating Hormone or FSH or rFSH or rhFSH).tw.	57786
27	gonadorelin/	38181
28	Gonadotropin Releasing Hormone\$.tw.	16215
29	Gonadotrophin Releasing Hormone\$.tw.	3366
30	GnRH\$.tw.	29904
31	exp estrogen/	300360
32	(?estrogen\$ or ?estradiol).tw.	240982
33	exp progesterone/	104475
34	exp Progesterone/ or progesterone.tw.	145928
35	(natural\$ adj2 cycle\$.tw.	3444
36	(artificial\$ adj2 cycle\$.tw.	633
37	(cycle\$ adj2 regimen\$.tw.	670
38	pituitary suppression.tw.	486
39	human menopausal.tw.	2684
40	spontaneous ovulation.tw.	615
41	(HCG adj3 trigger\$.tw.	1039
42	(stimulat\$ adj3 cycle\$.tw.	5831
43	exogenous steroid\$.tw.	708
44	exogenous steroid\$.tw.	708
45	(hormone adj2 therap\$.tw.	41571
46	(endometri\$ adj2 stimulat\$.tw.	835
47	15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46	605551
48	14 and 47	7970
49	Clinical Trial/	999716
50	Randomized Controlled Trial/	615254
51	exp randomization/	87897
52	Single Blind Procedure/	39662
53	Double Blind Procedure/	177011
54	Crossover Procedure/	64180
55	Placebo/	363424
56	Randomi?ed controlled trial\$.tw.	233156
57	Rct.tw.	37946
58	random allocation.tw.	2120
59	randomly allocated.tw.	35898
60	allocated randomly.tw.	2597
61	(allocated adj2 random).tw.	981
62	Single blind\$.tw.	25372
63	Double blind\$.tw.	216438
64	((treble or triple) adj blind\$.tw.	1215
65	placebo\$.tw.	315943
66	prospective study/	617823
67	retrospective study/	946322
68	49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67	3142742
69	case study/	80054
70	case report.tw.	444799
71	abstract report/ or letter/	1155908
72	69 or 70 or 71	1669914

73	68 not 72	3064021
74	(exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)	7230873
75	73 not 74	2969724
76	48 and 75	2373
77	76 – limited 2017 to 2020	1065

## Cochrane Register of Controlled Trials (CENTRAL)


Set	Search	Results
1	((Endometrial Preparation OR Cycle OR Natural Cycle OR Artificial Cycle OR Modified Natural Cycle OR Stimulated Cycle) AND (Pregnancy OR Pregnancy Outcomes OR Clinical Pregnancy OR Live Birth)) – Limited to 2017-2020	289

## CINAHL

Set	Search	Results
1	MM Cryopreservation+	1,545
2	TX Cryopreserv* N7 embryo*	792
3	TX Cryopreserv* N7 blastocyst*	80
4	MM Freezing	229
5	TX vitrification N7 embryo*	124
6	TX vitrification N7 blastocyst*	58
7	TX frozen N5 embryo*	1,186
8	TX freez* N5 embryo*	360
9	TX freez* N5 blastocyst*	22
10	TX frozen N5 blastocyst*	128
11	TX FET	1,353
12	(TX FET) AND (S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11)	1,353
13	MM ovulation induction	973
14	TX (ovar* N5 stimula*) or (ovulat* N5 induct*)	3,738
15	TX (endometri* N2prepar*)	181
16	MM Clomiphene	250
17	TX Clomiphene or TX clomid	1,128
18	TX Menotropin* or menopausal gonadotrop* or HMG)	3,785
19	MM Follicle-Stimulating Hormone	602
20	TX Follicle Stimulating Hormone or FSH	6,532
21	MM Gonadorelin	989
22	MM Pituitary Hormone Release Inhibiting Hormones	3
23	TX Gonadotropin-Releasing Hormone*	344
24	TX GnRH*	2,961
25	MM Estrogens	3,969
26	TX oestrogen or estrogen	46,066
27	MM Progesterone	1,914
28	TX Progesterone	17,782
29	TX natural* N2 cycle*	1,104
30	TX (artificial* N2 cycle*)	137

31	TX (cycle* N2 regimen*)	626
32	TX pituitary suppression	472
33	TX spontaneous* ovulat*	145
34	TX stimulat* N3 cycle	1,335
35	((TX stimulat* N3 cycle OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34)) AND (S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34)	65,832
36	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7OR S8 OR S9 OR S10 OR S11	4,623
37	(35 AND 36)	2,453
38	MH Clinical Trials+	303,701
39	PT Clinical trial	107,329
40	TX clinic* n1 trial*	393,652
41	TX(singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ((trebl* n1 blind*) or (trebl*n1 mask*) )	1,177,377
42	TX randomi* control *trial*	298,795
43	MH "Random Assignment"	63,059
44	TX random* allocat*	22,292
45	TX placebo*	125,194
46	MH Placebos	12,837
47	MH Quantitative Studies	27,500
48	TX allocat* random*	22,292
49	S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48	1,648,483
50	S37 AND S49	817
51	S37 AND S49	225
52	51 – Limited 2017-2020	158

Supplementary File 2 - Supplementary Table 2: Quality of Randomised Controlled Trials using the Revised Cochrane Risk-of-Bias tool 2



Greco 2016:

Domain	Signalling question	Response	Comments
Bias arising from the randomization process	1.1 Was the allocation sequence random?	Y	Two hundred thirty-six patients were included in the study and randomized in two groups according to computer-generated, not cancelled, simple randomization list with allocation assignment.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	N	Both the patient and the clinicians were informed of the assigned treatment. Difficult to conceal due to the nature of the intervention.
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	Baseline characteristics of the patients were not significantly different.
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
Bias due to deviations from intended interventions	2.1 Were participants aware of their assigned intervention during the trial?	Y	Both patients and clinicians were aware of the assigned intervention. However, due to the nature of the intervention, it would have been difficult to conceal.
	2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	
	2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups?	NA	
	2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?		
	2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?	NA	
	2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?	NA	
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
Bias due to missing outcome data	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y	Missing data was accounted for e.g. premature LH surge, inadequate endometrial thickness
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>		
Bias in measurement of the outcome	4.1 Was the method of measuring the outcome inappropriate?	N	Live birth rates is an appropriate outcome measurement
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	Definitions used for the measurement of outcomes was the same in both groups
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	Probably not, as the outcomes are objective rather than subjective
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PN	
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
	<b>Risk of bias judgement</b>	<b>Low</b>	
Bias in selection of the reported result	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	Y	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	PN	
	5.3 ... multiple eligible analyses of the data?	PN	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	



Sheikhi 2018:

Domain	Signalling question	Response	Comments
<b>Bias arising from the randomization process</b>	1.1 Was the allocation sequence random?	Y	The randomization was done at the start of the cycle using sequential numbering based on a computer-generated list that had been prepared at the Statistics Center of the Babol University of Medical Science and sent to them. Both participants and clinicians were aware of the treatment allocation.
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	N	
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	Baseline characteristics were fairly similar across both treatment groups.
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	Difficult to implement blinding and concealment due to the nature of the intervention.
<b>Bias due to deviations from intended interventions</b>	2.1 Were participants aware of their assigned intervention during the trial?	Y	Yes, as it is difficult to blind participants and clinicians due to the nature of the intervention
	2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	
	2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups?	NA	
	2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?	PY	Seven women were lost to follow-up (with explanations)
	2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?	NA	
	2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?		
	<b>Risk of bias judgement</b>	<b>Some concerns</b>	
<b>Bias due to missing outcome data</b>	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	PY	
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA	
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA	
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	
	<b>Risk of bias judgement</b>		
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	PN	Live births would have been a better measure of outcome, however as pregnancy loss after 20 weeks is very rare, it is still an appropriate outcome.
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	Outcome measurements are objective rather than subjective due to the nature of the study.
	4.3 Were outcome assessors aware of the intervention received by study participants?	Y	
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PN	Outcome measurements are objective rather than subjective due to the nature of the study.
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA	
<b>Risk of bias judgement</b>	<b>Low</b>		
<b>Bias in selection of the reported result</b>	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	PY	
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	PN	
	5.3 ... multiple eligible analyses of the data?	PN	
	<b>Risk of bias judgement</b>	<b>Low</b>	
<b>Overall bias</b>	<b>Risk of bias judgement</b>	<b>Some concerns</b>	

### Supplementary File 3 - Supplementary Table 3: Quality of Observational Studies using the Newcastle-Ottawa Scale


Authors		Alur-Gupta et al, 2018	Cardenas Armas et al, 2019	Chang et al, 2011	Givens et al, 2009	Le et al, 2017	Levi Setti et al, 2020	Pakes et al, 2020
	<b>Item</b>							
<b>A</b>	<b>Selection</b>							
	Exposed cohort is truly representative of the average	-	-	+	-	-	-	-
	Selection of the non-exposed cohort from the same community	-	-	+	-	-	-	-
	Exposure ascertained by a secure record or interview	+	+	+	+	+	+	+
	Demonstration of outcome of interest was not present at the start of the study	+	+	+	+	+	+	+
<b>B</b>	<b>Comparability*</b>							
	Study controls for additional variables	+	+	+	-	+	+	+
<b>C</b>	<b>Outcome</b>							
	Follow-up was adequate for outcome to occur	+	+	-	+	+	+	+
	Complete follow-up of all subjects was accounted for	+	+	+	+	+	+	+
	Subjects lost to follow up were unlikely to introduce bias	+	+	+	+	+	+	+
	Score (_/9)	6	7	7	5	6	6	6
	Conversion to AHRQ Standards	fair	good	good	fair	fair	fair	fair

AHRQ, Agency for Healthcare Research and Quality


\*Comparability may have up to a maximum of 2 points

## Supplementary File 4 - Supplementary Figure 1: Funnel Plot Analyses


**Funnel Plot for Positive hCG Rates**




**Funnel Plot for Live Birth Rates**




**Funnel Plot for Clinical Pregnancy Rates**




**Funnel Plot for Biochemical Pregnancy Rates**



**Funnel Plot for Clinical Pregnancy Rates – Sensitivity Analysis**




**Funnel plot for Miscarriage Rates**




## Supplementary File 5 - Supplementary Figure 2: Meta-analysis comparing rates of positive hCG, clinical pregnancy and live births in cycles with and without a corpus luteum – separated by study design


### Positive hCG Rates



### Clinical Pregnancy Rates




### Live Birth Rates




CL, Corpus luteum; CI, Confidence Interval

## Supplementary File 6 - Supplementary Figure 3: Meta-analysis comparing rates of pregnancy losses in cycles with and without a corpus luteum – separated by study design

### Biochemical Pregnancy Rates (Early Miscarriage)




### Miscarriage Rates



CL, Corpus luteum; CI, Confidence Interval

## Supplementary File 7 - Supplementary Figure 4: Meta-analysis comparing clinical pregnancy rates in cycles with and without a corpus luteum – sensitivity analysis



CL, Corpus Luteum; CI, Confidence interval